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Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients
with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission
tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is
emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper
is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.
1.Introduction
Lung cancer, with 80–85% being non-small-cell lung cancer
(NSCLC), is the leading cause of cancer-related death in
both men and women in the western world [1]. In 2008,
215,020 new cases are expected and 161,840 persons are
projected to die from the disease in the United States
[2]. Adequate therapeutic planning and prognosis is largely
depended on the early diagnosis and precise staging. Com-
puted tomography (CT) as a conditional and standard
method of diagnosis and staging lung cancer provides
excellent morphological information, but it has signiﬁcant
limitations in diﬀerentiating between benign and malignant
lesions either in an organ or in lymph nodes [3]. Positron
emission tomography (PET) is a unique imaging technique
that provides details of functional processes in the body.
However, the pool anatomic details obtained with PET make
it hard to locate lesions, which can lead to errors in the
diagnosis and staging of NSCLC. The combination of the 2
imagingproceduresprovidedbyintegratedPET/CTscanners
is relatively new, which was introduced into clinical practice
in 1998 [4]. Advances in positron emission tomography
combined with computed tomography (PET/CT) strive to
solve these problems by allowing the acquisition of both
functional and anatomical information of the whole body in
a single study and has gained wide acceptance over the last
few years, especially in North America and Western Europe,
and its clinical utility is expected to continue to rise [5]. The
purpose of this paper is to discuss the value of integrated
PET/CT in the staging of the non-small-cell lung cancer and
its health economics.
2.ImagingTechnique
A very small amount of a biological compound labeled
with a positron-emitting radionuclide, which is produced
in a cyclotron and has a very short half live, is injected
intravenously. A PET scanner measures the localization of
the tracer in tissue. The most commonly used radionuclide
is Fluoride (18F) for its relatively long half-life (110min).
Glucosewhichisusuallyusedtoprovideenergyforourbody,
is themost commonlyused biologic agent. Glucoseis labeled
with 18F to create the glucose analog 18F-ﬂuorodeoxyglucose
(18F-FDG) that is the most widely used radionuclide in
oncology because cancer cells have greater metabolic activity
compared with normal cells. The radionuclides used in PET
emit positrons as they decay. These positrons annihilate
after encountering an electron and produce a pair of2 Journal of Biomedicine and Biotechnology
photons that travel in opposite directions, which are then
detected by the PET scanner. The PET scan detects these
annihilation photons and is able to construct tomography
images including coronal, sagittal, and transverse manners,
which embody quantitative physiological, pathological, or
pharmacological information [6].
Cancer cells are capable of greater intracellular uptake
of FDG because of increased glucose transporters on the
cell membrane and increased activity of enzymes involved
in the glycolytic pathway. FDG is phosphorylated to FDG-
6-phosphate which, cannot be further metabolized and
remains trapped in the cells. Therefore, the uptake and
accumulation of malignant regions will be greater than
normal tissue cells and they will be displayed as abnormal
strong gather areas.
Due to the relatively poor spatial resolution of PET,
disease localization usually proved to be hard. To solve
this problem, anatomic and functional imaging has been
integrated into one diagnostic modality that is known as
image fusion. Image fusion can be performed at 3 diﬀerent
levels [7]: visual fusion, software fusion, and hardware
fusion. In traditional visual image fusion, the physician
compares 2 separate imaging modalities viewed next to each
other. The fusion takes place in his or her mind. In software
image fusion, PET and CT imaging are fused using software-
based algorithms, which creates 2D and 3D fusion images.
As far as integrated PET/CT is considered, hardware fusion
using a single detector provides the best coregistration of
physiologic and anatomic detail.
Hardware fusion is the most advanced and can make
best anatomic registration, but it is the most expensive and
the least accessible method. In the integrated PET/CT study,
low-dose CT, diagnostic CT and PET scans are all obtained
in a single time. Low-dose CT obtained at quiet respiration
for attenuation correction results in a lower noise emission
scan and faster examinations (reduction of whole body scan
times by at least 40%) and, thus, fewer motion artifacts and
a higher throughput [8]. The diagnostic CT, obtained with
the administration of contrast material, provides excellent
anatomic data. Fusion obtained using external software,
which creates 2D and 3D fusion images [9].
3. Staging
Accurate staging of patients with non-small-cell lung cancer
is critical in determining treatment strategy and predicting
prognosis. Nowadays we usually take TNM staging system,
which is maintained by the American Joint Committee on
Cancer and the International Union Against Cancer [10].
TNM staging system is based on a combination of ﬁndings:
the location and extent of the primary tumor (T), the
presence or absence of intrapulmonary, hilar or mediastinal
lymph node metastases (N), and the presence or absence of
extrathoracic metastases (M) [11, 12]. The combination of
T, N, and M staging is then used to give the tumor an overall
stage (I–IV), with the aim of grouping patients into stages
with similar prognosis. Survival rate and treatment options
also vary from stage to stage [10].
Based on adequate diagnosis and staging, personalized
treatment strategies can be selected to gain best prognosis
and to be cost-eﬀective. The recommended therapy [13]
for stage I disease is surgical resection, with stereotactic
body radiation therapy (SBRT) [14, 15] reserved for those
who are medically inoperable. Stage II disease is also
treated with surgery followed by adjuvant chemotherapy to
prevent disease recurrence. Stage IIIA disease has multiple
treatment options determined by the extent of regional
(nodal) involvement. Stage IIIA disease is often treated with
concurrent chemotherapy and radiation, adding surgical
resection (trimodality therapy) for those who are medically
ﬁt and have responded well to initial concurrent therapy.
Stage IIIB disease is treated with concurrent chemotherapy
and radiation. Stage IV disease is treated with systemic
therapy, chemotherapy, and/or molecular targeted agents, in
addition to radiotherapy for alleviating of painful lesions
or brain metastasis. Many studies have demonstrated that
integrated PET/CT is more accurate than CT alone, PET
alone [16, 17], and visually correlated PET/CT in evaluating,
the TNM status [18].
3.1. T Staging. T staging describes the location, size, and
extension of the primary tumor and the presence or absence
of satellite nodules. CT is an important imaging modality
for the evaluation of the primary tumor because of its
excellent anatomical resolution. But it is diﬃcult for it to
evaluate the invasion of the chest wall or involvement of the
mediastinum and diﬀerentiate tumors from postobstructive
atelectasis correctly [19].
FDG-PET gives more information about the metabolic
changes of the neoplasm but oﬀers little application in the T
staging of non-small-cell lung cancer, because of its limited
ability for precise anatomic location and size measurement.
PET is limited in detecting microscopic tumor deposits,
correctly evaluating extension of tumor and biological low
metabolism tumor, such as bronchoalveolar cell carcinoma,
carcinoidtumors,andsomeadenomas[18].Itisstrikingthat
PET alone are both upstaging and understaging for the T
staging of patients with NSCLC.
It has been shown that integrated PET/CT provided
more than the sum of PET and CT [20]. In particular, it
improves T staging [21]. Due to precise CT correlation with
the extent of 18F-FDG uptake, the location of the primary
tumor can be exactly deﬁned. It has been demonstrated
that integrated PET/CT provides important information on
mediastinal inﬁltration, chest wall inﬁltration, and diﬀeren-
tiation between tumor and peritumoral atelectasis [3]. It has
been found in many literatures [21] that PET/CT is the best
noninvasive imaging technique for the accurate prediction
of T staging. In one study of Wever et al. [18], integrated
PET/CT correctly predicted the T staging in patients with
NSCLC in 86% of cases versus 68% with CT, 46% with PET,
72% with visually correlated PET/CT.
3.2. N Staging. Accurate mediastinal staging is particularly
important, as in many cases the status of these nodes
will determine whether surgical resection of lung cancer isJournal of Biomedicine and Biotechnology 3
Table 1: Recent studies evaluating N staging with PET/CT compared with PET and CT.
Ref.
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
PET/CT PET CT PET/CT PET CT PET/CT PET CT PET/CT PET CT PET/CT PET CT
[25] 7 09 46 49 5
[26]9 5 7 7 8 7 6 9
[27] 5 49 27 48 2 8 1
[28] 6 59 77 99 0 9 2
[29] 8 66 9 8 57 1 6 44 3 9 5 8 8 8 5 7 1
[18] 8 38 3 8 38 48 1 6 87 57 1 6 09 08 98 8 8 4 8 2 7 4
[30] 8 48 4 8 56 1 8 5 7 4
[31] 56 65 100 89 90 83
[20] 8 57 0 8 46 9 8 4 6 9
A v e r a g e 7 38 3 7 49 18 1 7 37 17 1 5 29 08 98 8 8 6 8 2 7 3
possible [3]. The accuracy of CT for determining N staging
remains limited, because nodal staging with CT is based
on morphological characteristics. Lymph node size is used
as the only criterion to determine metastatic disease. The
current consensus considers a lymph node with a short-
axis diameter greater than 1cm as a predictor for metastasis
[22]. However, if postobstructive pneumonitis is present,
little correlation exists between the size of the mediastinal
lymph nodes and tumor involvement [23]. Normal-sized
regional lymph nodes may prove to be metastasizing upon
histological examination, and nodal enlargement can be due
to reactive hyperplasia or other nonmalignant conditions.
PET has been reported to increase diagnostic accuracy in
the diﬀerentiation of benign and malignant lesions and to
improve identiﬁcation of nodal metastasis. Functional scans
obtained with FDG PET not only are complementary to
those obtained with conventional modalities but also may
be more sensitive because alterations in tissue metabolism
generally precede anatomic change [24]. However, its poor
spatial detail and FDG being nonspeciﬁc tracer can lead to
inaccuracies, particularly in the areas of normal physiologic
uptake.
By integrating functional and anatomic data, PET/CT
improved N staging compared with PET or CT alone. Indeed
the beneﬁt of PET/CT compared with PET in nodal staging
appears to lie in a moderate increase in speciﬁcity and
positive predictive value for its additional exactly anatomic
information. Because of attaching metabolism information
of lymph node, PET/CT improves accuracy compared with
CT. Initial studies demonstrated a pooled average sensitiv-
ity, speciﬁcity, positive predictive value, negative predictive
value, and accuracy of PET/CT for detecting metastatic
lymph nodes of, respectively, 73%, 91%, 71%, 90%, and 86%
versus 83%, 81%, 71%, 89%, 82% of PET alone and 74%,
73%,52%,88%,73%ofCTalone.Theresultsofthesestudies
are summarised in Table 1 [18, 20, 25–31].
In one study performed by Darling et al. [25], of 22
patients with a PET/CT interpreted as positive for mediasti-
nal nodes, 8 did not have tumor. Based on PET/CT alone,
eight patients would have been denied potentially curative
surgery if the mediastinal abnormalities detected by PET/CT
had not been evaluated with an invasive mediastinal proce-
dure. PET/CT assessment of the mediastinum is associated
with a clinically relevant false-positive rate. When positive
mediastinal lymph nodes are detected, invasive mediastinal
staging must be performed [25]. While mediastinal lymph
nodes is negative, surgery can be done directly because of its
high negative predict value.
There is an ongoing controversy whether PET/CT scan
can reduce further invasive mediastinal staging. The general
consensus is that PET/CT can reduce mediastinoscopy for
high negative predict value. Perigaud et al. [32]r e p o r t e d
the speciﬁcity is high: patients with negative integrated
18F-FDG PET/CT can be operated upon directly without
invasive mediastinal staging. While one study of Metin et
al. [33] showed that PET/CT does not reduce the need
for invasive procedures in detecting lymph node metastasis
in aortopulmonary window. By integrating functional and
anatomic data, PET/CT is the best noninvasive method
for the detection of nodal metastasis, but mediastinoscopy
remains the gold standard [25, 33]. The results of imag-
ing are not conclusive and the probability of mediastinal
involvement is high (based on tumor size and location),
which are the indications for mediastinoscopy. Therefore,
mediastinoscopy is appropriate for patients with T2 and T3
lesions even if the PET/CT scan does not suggest mediastinal
node involvement. Mediastinoscopy may also be appropriate
to conﬁrm mediastinal node involvement in patients with
a positive PET/CT scan [12]. In general, the biopsy of the
lymph node with the highest stage by endoscopic bronchial
ultrasound (EBUS) or mediastinoscopy is suﬃcient for fur-
thertreatmentdecisions.However,notallmediastinallymph
nodes are routinely reachable by EBUS or mediastinoscopy
(paraaortic region, aortopulmonary window). Recently, it
has been demonstrated that PET can assist mediastinoscopy
[3].
3.3. M Staging. Despite radical surgical treatment of poten-
tially curable NSCLC the overall 5-year survival rate remains
low (20–40%). One reason for this is undetected extratho-
racic metastases, which cause underestimation of the tumor4 Journal of Biomedicine and Biotechnology
stage[3].NSCLCmostmetastasizestothebrain,bones,liver,
and adrenal glands [34].
Radionuclide bone scanning with 99mTc-methylene di-
phosphonateisusuallyusedinthedetectionofoccultskeletal
metastases; however, it has high false-positive rate [35]. The
accuracy of bone scintigraphy to detect bone metastases was
87% versus 98% of 18F-FDG PET. PET scanning is more
sensitive and accurate than bone scanning for the detection
of skeletal metastases (91% and 94% versus 75% and 85%,
resp.), with a high PPV of 98% if the ﬁndings on PET/CT
scanning are concordant, but decreases to 61% if the CT scan
is negative [36].
Adrenalmetastasesfromlungcancerarecommon,found
in approximately 33% of patients at autopsy [12]. In patients
with NSCLC, however, many solitary adrenal masses are not
malignant. So it is very critical in distinguishing between a
metastatic lesion and an adenoma. Diagnostic CT evaluates
adrenal metastases based on tumor size and attenuation
value, which may lead to false negative or false positive
results. Any adrenal mass found on a preoperative CT
scan in a patient with lung cancer should be biopsied
to rule out benign adenoma. For magnetic resonance
imaging (MRI), the ability to distinguish metastases from
adenomas has improved considerably with the introduction
of more sophisticated MR imaging techniques such as fat-
saturated, chemical shift and dynamic gadolinium-enhanced
MR imaging. One group of investigators correlated the MR
imaging ﬁndings with histological results in 114 patients
with 134 adrenal masses. Combined chemical shift and
dynamic gadolinium-enhanced MR imaging was found to
have a sensitivity of 91% and a speciﬁcity of 94% for
diﬀerentiating benign from malignant adrenal masses [37].
In fact, PET scanning is useful in distinguishing benign from
malignant adrenal masses detected on CT scanning [35, 38].
In some studies, integrated PET/CT is a useful diagnostic
modality for adrenal gland imaging in cancer patients,
since it allows early detection and accurate localization of
adrenal lesions and diﬀerentiation of metastatic nodules
from benign lesions, thereby facilitating treatment planning
[39, 40]. However, some adenoma may show increased
FDG, which will produce false positive results. Hemorrhage,
necrosis [37, 41], and subcentimeter metastatic lesions may
have low FDG uptake, which will lead to produce false
negative results. In one study performed by Perri et al. [42],
they demonstrated that the combination of standardized
uptake value (SUV) and CT histogram analysis allowed us
to signiﬁcantly improve the PET/CT diagnostic accuracy
for characterizing adrenal lesions, leading to a signiﬁcant
reduction in the number of false positive cases. In another
study, Chong et al. [43] reported that ﬁne-needle aspiration
biopsy should be performed only if clinical and imaging
studies are inconclusive.
In the newly adopted 7th edition of the TNM classi-
ﬁcation for lung cancer, NSCLC metastatic is subdivided
into M1a for those cases with pleural nodules or malignant
pleural or pericardial eﬀusion and additional pulmonary
nodules in the contralateral lung and M1b for those cases
with other distant metastases disease [44]. The presence
of pleural or pericardial nodules on CT can conﬁrm the
diagnosis of M1a disease, but these ﬁndings are often absent.
PET can usually suggest the diagnosis of malignant pleural
disease by showing increased focal or diﬀuse FDG uptake,
but localization to the pleura or pericardium is not always
clear for its poor resolution. Statistically, PET/CT has proven
to be superior to either technique the in evaluation of
metastatic pleural disease.
PET/CT has a low sensitivity in detecting brain metas-
tases because of brain cells with high glucose uptake in
nature. Therefore, in patients with neurological symptoms,
an MRI of the brain should be performed, because of its high
resolution, while Salskov et al. reported that PET using 18F-
ﬂuorothymidine(18F-FLT)foritslowphysiologicaluptakein
brain can be used in detecting brain metastases [45].
PET/CT can improve the accuracy in the staging of
non-small-cell lung cancer. For N staging, PET/CT scanning
possessing high negative predict value can reduce unnec-
essary mediastinoscopy. Although some authors found no
signiﬁcant reduction in the number of avoidable thoraco-
tomies performed when employing additional PET imaging
in NSCLC, the general consensus is that PET can reduce
needless thoracotomy rates. In one study of Fischer et al.
[46], a total of 189 patients were enrolled and randomly
assigned to either the PET/CT group (98 patients) or the
conventional-staging group (91 patients). After staging, 60
patients in the PET/CT group (61%) and 73 patients in the
conventional-staging group (80%) were considered to have
operable disease and underwent thoracotomy (P = 0.004),
while a total of 21 of 98 patients in the PET/CT group
(21%) and 38 of 91 in the conventional-staging group (42%)
underwent a futile thoracotomy. In other words, for every
ﬁve PET/CT scans, one futile thoracotomy was avoided.
Therefore, they reported that the use of PET/CT for pre-
operative staging of NSCLC reduced both the total number
of thoracotomies and the number of futile thoracotomies.
Two randomized trials have assessed the clinical eﬀect of
PET alone. A trial by van Tinteren et al. [47] showed that
the number of futile thoracotomies was signiﬁcantly reduced
in 19/82 patients compared to 29/96 patients, based on the
addition of 18F-FDG PET to the diagnostic algorithm. A
randomized trial, however, did not show that adding PET
reduced the number of thoracotomies [48]. We have to
notice that imaging strategies based on PET/CT may help
identify advanced disease and prevent futile thoracotomies
in patients with NSCLC, but it also has false positive results
that incorrectly upstage disease in some patients.
Despite an extensive literature documenting the sensitiv-
ity and speciﬁcity of PET/CT scanning, rarely publications
exist to demonstrate an increased survival of patients with
NSCLC due to the use of PET scanning. The studies of
Fontaine et al. [49] showed that the introduction of routine
PETscanningdidnotresultinimprovedsurvivalintheshort
or long term for patients undergoing resections for stage
IA, IB and stage II, while a signiﬁcant increased survival for
s t a g eI I Ip r i m a r yl u n gc a n c e r( P = 0.03). They concluded
that patients with stage III non-small-cell lung cancer should
undergo PET scanning prior to surgical resection.
While in the study of Fischer et al. [46] 98 patients
were assigned to PET/CT group, 91 patients were assignedJournal of Biomedicine and Biotechnology 5
to the conventional-staging group. They found that there
were no signiﬁcant diﬀerences in survival between the two
groups; median survival was 31 months in the PET/CT
group and 49 months in the conventional-staging group
(P = 0.29). Therefore, they reported that the use of PET/CT
for preoperative staging of NSCLC did not improve overall
survival rate.
4. The Cost-Effectiveness of PET/CT in
NSCLCStaging
A diagnostic eﬀectiveness of PET/CT for staging NSCLC
and superiority to conventional cancer imaging modalities
has been demonstrated by many studies [18, 20, 50, 51].
However, whether this technology should be widely applied
in the staging of NSCLC remains at debate for its high
examination costs. In addition, this may be oﬀset in part
by improvements in staging accuracy and examination times
[52]. In recent years, incremental cost-eﬀectiveness ratios
(ICER), quality-adjusted life year (QALY) et al., were used to
evaluate healthy economic of this technology. Several cost-
eﬀectiveness analyses have been published evaluating PET in
lung cancer staging, though data speciﬁcally on PET/CT is
absence.
In a randomized trial performed by van Tinteren et
al. [47], 96 patients were randomly assigned conventional
workup (CWU) and 92 conventional workup and PET
(CWU + PET). In the CWU group, 39 (41%) patients had
futilethoracotomies,comparedwith19(21%)intheCWU+
PETgroup(relativereduction51%,P = 0.003).Theaddition
of PET to CWU prevented futile surgery in one out of ﬁve
patients with suspected NSCLC. Despite the additional PET
costs,thetotalcostswerelowerinthePETgroup,mainlydue
to a reduction in the number of futile operations and general
hospital days especially intensive care days. The additional
use of PET in the staging of patients with NSCLC is feasible
and safe, and it saves costs from a clinical and an economic
perspective.
A study performed in Canada showed that PET for
staging NSCLC without CT coregistration, compared with
CT alone, led to a cost savings of $1,455 combined with an
increase in life expectancy of 3.1d [53]. Recently, the diag-
nostic value and cost-eﬀectiveness have also been approved
by the German health care system [54].
In one study based on 172 NSCLC patients who
underwent diagnostic, contrast-enhanced helical CT and
integrated PET/CT, Schrey¨ ogg et al. [55]reported that the
incremental cost-eﬀectiveness ratios (ICER) per correctly
staged patient were $3,508 for PET/CT versus CT alone.
The ICER per quality-adjusted life year (QALY) gained were
$79,878 for PET/CT versus CT alone, decreasing to $69,563
assumingareducedlossofutility(0.10QALY)duetosurgical
morbidity. The study showed that costs for PET/CT are
within the commonly accepted range for diagnostic tests,
therapies, or staging from the payer’s perspective.
Søgaard et al. [56] performed a randomized clinical trial
in which 189 patients were allocated to conventional staging
(n = 91) or conventional staging + PET/CT (n = 98) and
followed for 1 year after which the numbers of futile thora-
cotomies in each group were monitored. They showed that
implementation of PET/CT into the diagnostic algorithm of
staging NSCLC is cost-eﬀective. The ICER was calculated
to be 19,314 C, meaning that PET/CT is cost-eﬀective if
the provider’s willingness to pay (WTP) is 50,000 C per
avoided futile thoracotomy. Including comorbidity-related
costs, we found that the cost-eﬀectiveness of PET/CT for
staging NSCLC depends on the WTP in order to avoid
a futile thoracotomy for which there is no true threshold
value. A futile thoracotomy can be futile either because it is
performed in patients with a benign lung lesion or because it
is performed in patients with unresectable, end-stage cancer.
5. The Limitationof PET/CTin Stagingof
Non-Small-CellLungCancer
Although PET/CT is an accurate and noninvasive method
in the staging of non-small-cell lung cancer, many pitfalls
exist. Imprecise physiologic and anatomic registration, most
common adjacent to the diaphragm and heart, can lead
to misregistration artifact [57]. Misregistration occurs as a
result of diﬀerences in the position of the patient during
the CT and PET examination. This may occur either as
a result of voluntary motion of the patient during the
examination or more commonly because of discrepancies
in the phases of the patient’s respiratory cycle during the
CT and PET examinations [52]. Misregistration can lead
to incorrect anatomical registration of PET and CT images,
which can aﬀect the accurate localization of uptake within
pulmonary masses or lymph nodes. Cohade et al. [58]
reported the mean discrepancy between the location of
pulmonary lesions on PET and CT was approximately 7mm,
with better registration at the lung apices than bases. These
misregistrations can make micro-lesions missed, resulting in
false negative results.
As a general rule uptake of SUV(max) ≥ 2.5 was consid-
ered to indicate a malignant lesion, and SUV(max) < 2.5 was
considered to indicate a benign lesion [59]. Many processes
with increased metabolic activities show increased FDG
uptake on PET/CT imaging. Several benign lesions that have
increased glucose metabolism can accumulate FDG and can
be misinterpreted as malignant, such as infection, inﬂamma-
tion, and infarct [10]. In addition, physiological uptake of
FDG usually found in the brain, heart, gastrointestinal and
genitourinary tracts, and striated muscles show increased
FDG uptake on PET/CT imaging. Iatrogenic causes of focal
or diﬀuse FDG uptake include, granulation tissue, healing
wounds, chest tubes and gastrotomy tubes, percutaneous
needle biopsy, and mediastinoscopy [60]. These increased
FDG uptake can lead to false positive results. There is some
evidence to suggest that “dual-time-point” imaging may be
helpfulindiﬀerentiatingmalignantversusinﬂammatoryand
infectious processes [61].
False-negative FDG uptake includes technological lim-
itations of PET/CT and inherent properties of neoplasm.
Lesions that measure less than two to three times than
the spatial resolution of the scanner will appear less active6 Journal of Biomedicine and Biotechnology
and a lower SUV due to the partial volume eﬀect. Lesions
containing little cells, low metabolic neoplasm, and highly
diﬀerentiated tumors can lead to false negative results. It is
important for us to know these potential pitfalls in order to
get more accuracy staging of non-small-cell lung cancer.
6. Conclusion
The accurate staging of NSCLC is important in determining
optimal treatment strategy and getting a better prognosis.
Integrated PET/CT combining the beneﬁts of PET and
CT and minimizing their limitations is a potential tool in
the staging of non-small-cell lung cancer. It reduces futile
treatment and its associated morbidity and cost, improving
the quality of life and being cost-eﬀectiveness.
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